Neisseria meningitidis serogroup B: Laboratory correlates of protection

FEMS Immunology and Medical Microbiology

Volumn 34, Issue 2, 2002, Pages 89-96

  Vermont, Clementien ^a,b   Van Den Dobbelsteen, Germie ^b  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Correlates of protection; Laboratory assay; Meningococcal disease; Neisseria meningitidis serogroup B vaccine

Indexed keywords

ANTIBODY; ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G; IRON DEXTRAN; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE VACCINE; PORIN; PORIN A; PORIN B; PROTEIN A; TRANSFERRIN; TRANSFERRIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOBLOTTING; IMMUNOGENICITY; INFECTION RISK; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SEROTYPE; SERUM BACTERICIDAL ACTIVITY; SHORT SURVEY; T LYMPHOCYTE; VACCINATION;

ANIMALS; CHILD, PRESCHOOL; CLINICAL TRIALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MODELS, ANIMAL; NEISSERIA MENINGITIDIS, SEROGROUP B; OPSONIN PROTEINS; PHAGOCYTOSIS; POLYSACCHARIDES, BACTERIAL; SERUM BACTERICIDAL TEST; T-LYMPHOCYTES;

EID: 0037063986     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(02)00342-5     Document Type: Short Survey

References (59)

1. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129:1969;1327-1348.
2. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1969;1307-1326.
3. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med. 129:1969;1367-1384.
4. Griffiss J.M., Brandt B.L., Broud D.D., Goroff D.K., Baker C.J. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J. Infect. Dis. 150:1984;71-79.
5. Mandrell R.E., Zollinger W.D. Human immune response to meningococcal outer membrane protein epitopes after natural infection or vaccination. Infect. Immun. 57:1989;1590-1598.
6. Pollard A.J., Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine. 19:2001;1327-1346.
7. Jennings H.J., Roy R., Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 137:1986;1708-1713.
8. Jennings H.J., Gamian A., Ashton F.E. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis. J. Exp. Med. 165:1987;1207-1211.
9. de Moraes J.C., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 340:1992;1074-1078.
10. Bjune G., et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 338:1991;1093-1096.
11. Boslego J., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine. 13:1995;821-829.
12. Morley S.L., et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr. Infect. Dis. J. 20:2001;1054-1061.
13. Perkins B.A., et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis. 177:1998;683-691.
14. Wedege E., Hoiby E.A., Rosenqvist E., Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66:1998;3223-3231.
15. Tappero J.W., et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. J. Am. Med. Assoc. 281:1999;1520-1527.
16. Cartwright K., Morris R., Rumke H., Fox A., Borrow R., Begg N., Richmond P., Poolman J. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine. 17:1999;2612-2619.
17. de Kleijn E.D., et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine. 18:2000;1456-1466.
18. Verheul A.F., Van Gaans J.A., Wiertz E.J., Snippe H., Verhoef J., Poolman J.T. Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein conjugates evoke outer membrane protein- but not LPS-specific bactericidal antibodies in mice: influence of adjuvants. Infect. Immun. 61:1993;187-196.
19. Peltola H., et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med. 297:1977;686-691.
20. Borrow R., Andrews N., Goldblatt D., Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect. Immun. 69:2001;1568-1573.
21. Lehmann A.K., Halstensen A., Naess A., Vollset S.E., Sjursen H., Bjune G. Immunization against serogroup B meningococci. Opsonin response in vaccinees as measured by chemiluminescence. APMIS. 99:1991;769-772.
22. Lehmann A.K., Halstensen A., Aaberge I.S., Holst J., Michaelsen T.E., Sornes S., Wetzler L.M., Guttormsen H. Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB. Infect. Immun. 67:1999;2552-2560.
23. Ison C.A., et al. Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microb. Pathog. 27:1999;207-214.
24. Milagres L.G., et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:1994;4419-4424.
25. Maslanka S.E., et al. The Multilaboratory Study Group . Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin. Diagn. Lab. Immunol. 4:1997;156-167.
26. Santos G.F., Deck R.R., Donnelly J., Blackwelder W., Granoff D.M. Importance of complement source in measuring meningococcal bactericidal titers. Clin. Diagn. Lab. Immunol. 8:2001;616-623.
27. Zollinger W.D., Mandrell R.E. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:1983;257-264.
28. Mountzouros K.T., Howell A.P. Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis. J. Clin. Microbiol. 38:2000;2878-2884.
29. Rodriguez T., et al. Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericida assay. Clin. Diagn. Lab. Immunol. 9:2002;109-114.
30. Ross S.C., Rosenthal P.J., Berberich H.M., Densen P. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis. 155:1987;1266-1275.
31. Michaelsen T.E., Aase A., Kolberg J., Wedge E., Rosenqvist E. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria. Vaccine. 19:2001;1526-1533.
32. Lehmann A.K., Gorringe A.R., Reddin K.M., West K., Smith I., Halstensen A. Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes. Infect. Immun. 67:1999;6526-6532.
33. Guttormsen, H.-K., Wetzler, L.M. and Solberg, C.O. (1994) In: Neisseria 94, Proceedings of the Ninth International Pathogenic Neisseria Conference (Evans, J.S., Yost, S.E., Maiden, M.C.J. and Feavers, I.M., Eds.), Winchester, UK.
34. Aase A., Bjune G., Hoiby E.A., Rosenqvist E., Pedersen A.K., Michaelsen T.E. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 63:1995;3531-3536.
35. Wiertz E.J., van Gaans-van den Brink J.A., Gausepohl H., Prochnicka-Chalufour A., Hoogerhout P., Poolman J.T. Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis. J. Exp. Med. 176:1992;79-88.
36. van der Voort E.R., van Dijken H., Kuipers B., van der Biezen J., van der Ley P., Meylis J., Claassen I., Poolman J. Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine. Infect. Immun. 65:1997;5184-5190.
37. Naess L.M., Oftung F., Aase A., Wetzler L.M., Sandin R., Michaelsen T.E. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine. Infect. Immun. 66:1998;959-965.
38. Pollard A.J., et al. Cellular immune responses to Neisseria meningitidis in children. Infect. Immun. 67:1999;2452-2463.
39. Perez O., Lastre M., Lapinet J., Bracho G., Diaz M., Zayas C., Taboada C., Sierra G. Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine. Infect. Immun. 69:2001;4502-4508.
40. de Kleijn E., et al. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine. 20:2001;352-358.
41. Vermont C.L., van Dijken H.H., van Limpt C.J.P., de Groot R., van Alphen L., van den Dobbelsteen G.P.J.M. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle (OMV) vaccine. Infect. Immun. 70:2002;584-590.
42. Naess L.M., Aarvak T., Aase A., Oftung F., Hoiby E.A., Sandin R., Michaelsen T.E. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine. 17:1999;754-764.
43. Guttormsen H.K., Wetzler L.M., Solberg C.O. Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease. Infect. Immun. 62:1994;1437-1443.
44. Sjursen H., Wedege E., Rosenqvist E., Naess A., Halstensen A., Matre R., Solberg C.O. IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination. APMIS. 98:1990;1061-1069.
45. Naess L.M., Rosenqvist E., Hoiby E.A., Michaelsen T.E. Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. J. Immunol. Methods. 196:1996;41-49.
46. Richmond P., Borrow R., Goldblatt D., Findlow J., Martin S., Morris R., Cartwright K., Miller E. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. 183:2001;160-163.
47. Goldblatt D., Vaz A.R., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177:1998;1112-1115.
48. Usinger W.R., Lucas A.H. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67:1999;2366-2370.
49. Anttila M., Eskola J., Ahman H., Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis. 177:1998;1614-1621.
50. Wedege E., Bolstad K., Wetzler L.M., Guttormsen H. IgG antibody levels to meningococcal porins in patient sera: comparison of immunoblotting and ELISA measurements. J. Immunol. Methods. 244:2000;9-15.
51. Holbein B.E., Jericho K.W., Likes G.C. Neisseria meningitidis infection in mice influence of iron, variations in virulence among strains, and pathology. Infect. Immun. 24:1979;545-551.
52. Oftung F., Lovik M., Andersen S.R., Froholm L.O., Bjune G. A mouse model utilising human transferrin to study protection against Neisseria meningitidis serogroup B induced by outer membrane vesicle vaccination. FEMS Immunol. Med. Microbiol. 26:1999;75-82.
53. Mackinnon F.G., Gorringe A.R., Funnell S.G., Robinson A. Intranasal infection of infant mice with Neisseria meningitidis. Microb. Pathog. 12:1992;415-420.
54. Salit I.E., Van Melle E., Tomalty L. Experimental meningococcal infection in neonatal animals: models for mucosal invasiveness. Can. J. Microbiol. 30:1984;1022-1029.
55. Schmidt S., Zhu D., Barniak V., Mason K., Zhang Y., Arumugham R., Metcalf T. Passive immunization with Neisseria meningitidis PorA specific immune sera reduces nasopharyngeal colonization of group B meningococcus in an infant rat nasal challenge model. Vaccine. 19:2001;4851-4858.
56. Saukkonen K., Abdillahi H., Poolman J.T., Leinonen M. Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model new prospects for vaccine development. Microb. Pathog. 3:1987;261-267.
57. Saukkonen K. Experimental meningococcal meningitis in the infant rat. Microb. Pathog. 4:1988;203-211.
58. Sierra G.V., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:1991;195-210.
59. Longworth E., Borrow R., Goldblatt D., Balmer P., Dawson M., Andrews N., Miller E., Cartwright K. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine. 20:2002;2592-2596.